BerGenBio is a clinical-stage biopharmaceutical company focused on developing a pipeline of first-in-class selective AXL kinase inhibitors to treat multiple aggressive cancers. BerGenBios lead product, BGB324, is a selective, potent and orally available small molecule AXL inhibitor. It is in Phase II clinical development, as a single agent and in combination with marketed immuno-oncology drugs, in three cancer indications with blockbuster potential, including acute myeloid leukaemia (AML), advanced non-small-cell lung cancer (NSCLC) and triple negative breast cancer (TNBC). The company is also developing a diversified pre-clinical pipeline of selective AXL inhibitors including biologics and small molecules.